Business Standard

Friday, February 07, 2025 | 01:50 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Piramal Pharma Ltd News

CDMO revenues to touch $1.2 bn by FY30: Piramal Pharma chairperson

Says that their growth is led by innovation related work

CDMO revenues to touch $1.2 bn by FY30: Piramal Pharma chairperson
Updated On : 29 Jan 2025 | 8:57 PM IST

Piramal Pharma Q3 FY25 results: PAT falls 63% to Rs 3.6 cr, revenue up 12%

Sequentially, revenue from operations declined by 1.67 per cent, with PAT falling 83.7 per cent

Piramal Pharma Q3 FY25 results: PAT falls 63% to Rs 3.6 cr, revenue up 12%
Updated On : 28 Jan 2025 | 9:42 PM IST

Piramal Pharma surges 4% after launching drug for psychiatric disorders

Piramal Pharma share price gained 3.87 per cent at Rs 252.05 a piece on the BSE in Thursday's intraday trade

Piramal Pharma surges 4% after launching drug for psychiatric disorders
Updated On : 23 Jan 2025 | 11:39 AM IST

Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed

The uptick in Piramal Pharma share price came after domestic brokerage JM Financial initiated coverage with 'Buy' for a target price of Rs 340

Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed
Updated On : 17 Dec 2024 | 10:05 AM IST

CDMO shares under pressure; Neuland, Laurus, Syngene tank up to 12%

Thus far in the calendar year 2024 (CY24), the market price of Neuland Laboratories has zoomed 216%, Piramal Pharma (88%), Divi's Labs (53%) and Jubilant Pharmova (52%)

CDMO shares under pressure; Neuland, Laurus, Syngene tank up to 12%
Updated On : 09 Dec 2024 | 11:31 AM IST

Piramal Pharma to pay $407,400 to US-based VetDC Inc to settle dispute

Piramal Pharma on Friday said it will pay USD 407,400 to US-based VetDC, Inc to settle a dispute over rejected batches of a product. Piramal Pharma Solutions Inc, a unit of the company, and VetDC, Inc have entered into a settlement agreement for an amount of USD 407,400, the drug maker said in a regulatory filing. VetDC had claimed damages on account of rejection of certain batches of product manufactured and supplied by Piramal Pharma Solutions Inc. "While the company continues to believe that its legal stand is appropriate against claims made by VetDC and maintains that it has defence to VetDC's claims of liabilities and damages, in order to solely avoid continued legal costs and uncertainties of protracted litigation, the Company and VetDC have both decided to settle," Piramal Pharma said. The company shall have no responsibility for any other costs beyond the amount of USD 407,400, it added. "This settlement will not have a significant impact on the financial position of the .

Piramal Pharma to pay $407,400 to US-based VetDC Inc to settle dispute
Updated On : 07 Dec 2024 | 12:09 AM IST

Piramal Pharma soars 13% on heavy volumes; up 42% in 2 weeks post Q2 show

Till 12:35 pm; a combined 32.3 million shares representing 2.43 per cent of total equity of PPL changed hands on the NSE and BSE.

Piramal Pharma soars 13% on heavy volumes; up 42% in 2 weeks post Q2 show
Updated On : 06 Nov 2024 | 1:03 PM IST

Piramal Pharma stock hits new, soars 25% in 6 days on strong Q2 results

Over the long term, the management remains committed to achieving the company's financial goals of $2 billion revenue with 25 per cent EBITDA margin and 1x net debt / EBITDA by FY30.

Piramal Pharma stock hits new, soars 25% in 6 days on strong Q2 results
Updated On : 31 Oct 2024 | 3:10 PM IST

Piramal Pharma deploying $85 mn capex this fiscal: Nandini Piramal

Piramal Pharma is utilising a capex of about USD 85 million for various initiatives, including capacity expansion, maintenance and de-bottlenecking of CDMO sites, in the current fiscal, according to its Chairperson Nandini Piramal. The Mumbai-headquartered firm, which aims to cross USD 2 billion in revenue by FY30, has already invested around USD 30 million in the first half of the ongoing fiscal on the initiatives. "We expect the capex this year to be at a similar level as last year, which is about USD 85 million," Piramal told PTI in an interaction. A part of the capex is planned for the domestic market while some of it would also go into the US business, she added. "Some part of it, around USD 30 million, is maintenance capex, and the rest would go into capacity expansion in Telangana and Dahej (Gujarat) plants and also towards de-bottlenecking of some of the CDMO sites," Piramal noted. The company last week reported over four-fold increase in consolidated net profit at Rs 23 c

Piramal Pharma deploying $85 mn capex this fiscal: Nandini Piramal
Updated On : 27 Oct 2024 | 12:11 PM IST

Piramal Pharma Q2FY25 results: Net profit jumps over 4-fold to Rs 23 crore

Piramal Pharma on Thursday reported over four-fold increase in consolidated net profit at Rs 23 crore for the second quarter ended September. The Mumbai-based company had reported a net profit of Rs 5 crore in the July-September quarter of last fiscal. Revenue from operations rose to Rs 2,242 crore in the second quarter as compared with Rs 1,911 crore in the year-ago period, Piramal Pharma said in a statement. "We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent growth in our CDMO business which has witnessed a good pick-up in innovation-related work and on-patent commercial revenues," Piramal Pharma Chairperson Nandini Piramal said. To sustain this growth momentum and to capitalise on rising demand for sterile fill-finish capabilities, the company has announced a USD 80 million expansion plan at the Lexington facility which is expected to be completed by the FY27 end, she added. "In

Piramal Pharma Q2FY25 results: Net profit jumps over 4-fold to Rs 23 crore
Updated On : 24 Oct 2024 | 11:58 AM IST

Piramal Pharma hits all time high, soars 13%; here's what's driving stock

Piramal Pharma's company's revenue for the quarter under review stood at Rs 2,242 crore as compared to Rs 1,911 crore which implies an increase of 17 per cent Y-o-Y

Piramal Pharma hits all time high, soars 13%; here's what's driving stock
Updated On : 24 Oct 2024 | 11:18 AM IST

Pharmaceutical firm Piramal Pharma eyes to double revenue to $2 bn by FY30

Eyeing tripling of Ebitda and bringing down net debt during the same period

Pharmaceutical firm Piramal Pharma eyes to double revenue to $2 bn by FY30
Updated On : 25 Sep 2024 | 4:11 PM IST

Piramal Pharma soars 9% as co targets 2x revenue, 3x Ebitda margin by FY30

Piramal Pharma aims to achieve over $2 billion in revenue by FY30, which implies 2 times growth in revenue compared with FY24

Piramal Pharma soars 9% as co targets 2x revenue, 3x Ebitda margin by FY30
Updated On : 25 Sep 2024 | 1:00 PM IST

Piramal Pharma hits record high in weak market; surges 12% on heavy volumes

As many as 43.42 million equity shares, representing 3.3 per cent of total equity of the pharma company, had changed hands on the NSE till afternoon

Piramal Pharma hits record high in weak market; surges 12% on heavy volumes
Updated On : 04 Sep 2024 | 2:20 PM IST